DEF: Tactile Medical Sets 2026 Annual Meeting Agenda, Details Executive Pay

Tactile Systems Technology, Inc. announces its 2026 Annual Meeting of Stockholders agenda, including director elections, auditor ratification, executive compensation approval, and a corporate governance amendment.

Summary

• The 2026 Annual Meeting of Stockholders is scheduled for May 6, 2026, at 9:00 a.m. CDT in Minneapolis, MN.
• Stockholders will vote on the election of nine directors, the ratification of Grant Thornton LLP as the independent registered public accounting firm for 2026, an advisory vote on 2025 executive compensation, and an amendment to the Certificate of Incorporation regarding director removal.
• The Board of Directors recommends voting FOR all proposals.
• For 2025, CEO Sheri L. Dodd's total compensation was $3,466,916, which included a base salary of $675,000 and a Management Incentive Plan (MIP) payment of $737,438.
• The company achieved 2025 revenue of $329.5 million, exceeding its target of $328 million, and Adjusted EBITDA of $44.8 million, significantly above its target of $37.2 million.
• The 2025 MIP payout was 115% of the target dollar amount, driven by strong performance in both revenue and Adjusted EBITDA.
• The 2025 Performance Stock Units (PSUs) for the 2025 performance year achieved a weighted payout of 128.9% of target, based on 2025 revenue of $329.5 million and an Adjusted EBITDA Margin of 13.5%.
• Net Income for 2025 was $19,086 thousand, an increase from $16,960 thousand in 2024.
• The CEO pay ratio for 2025 was 39:1, comparing the CEO's $3,466,916 compensation to the median employee's $88,317.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to strong financial performance against internal targets for 2025, particularly in revenue and Adjusted EBITDA, which drove higher incentive payouts. The proposed governance changes also reflect a commitment to best practices. However, the TSR underperformance relative to the peer group tempers overall enthusiasm.

Positives

• 2025 revenue of $329.5 million exceeded the target of $328 million, indicating strong sales performance.
• 2025 Adjusted EBITDA of $44.8 million significantly surpassed the target of $37.2 million, demonstrating robust operational efficiency.
• The Management Incentive Plan (MIP) for 2025 resulted in a 115% payout, reflecting the company's success in achieving its corporate performance goals.
• Performance Stock Units (PSUs) for the 2025 performance year achieved a 128.9% payout, indicating strong achievement against long-term incentive metrics.
• Net Income increased by 12.5% from $16,960 thousand in 2024 to $19,086 thousand in 2025.
• Adjusted EBITDA increased by 20.8% from $37,050 thousand in 2024 to $44,772 thousand in 2025.
• The proposed amendment to the Certificate of Incorporation to allow director removal with or without cause by a majority vote aligns with modern corporate governance best practices and Delaware law.
• Corporate governance highlights include an independent Chairman, fully independent board committees, and annual election of all directors, promoting strong oversight.
• Executive compensation is designed with challenging performance goals, stock ownership guidelines, and a clawback policy, aligning management interests with stockholders.

Risks

• The proxy statement includes a cautionary note regarding forward-looking statements, indicating that actual results could differ materially from expectations due to significant risks, uncertainties, and changes in circumstances.
• A detailed discussion of risks and uncertainties that could cause actual results and events to differ materially is included in the 'Risk Factors' section of the company's Annual Report on Form 10-K for the year ended December 31, 2025.

Future Outlook

The filing contains a general cautionary note regarding forward-looking statements, indicating that future performance and results are subject to significant risks and uncertainties that could cause actual results to differ materially. It refers readers to the company's Annual Report on Form 10-K for the year ended December 31, 2025, for a detailed discussion of these risks.

Management Comments

• Our mission is to reveal and treat people with underserved chronic conditions and help them care for themselves at home.
• Our unique offering includes advanced, clinically proven pneumatic compression and mobile airway clearance devices, as well as continuity of care services provided by a national network of product specialist and trainers, reimbursement experts, patient advocates and clinical staff.
• This combination of products and services ensures that every year tens of thousands of patients receive the at-home treatment necessary to better manage their chronic conditions.
• In addition to improving the quality of life for patients with chronic conditions, our solutions help increase clinical efficacy and reduce overall healthcare costs.

Industry Context

StockSavvy.ai notes that Tactile Medical operates in the specialized and growing medical device industry, focusing on chronic conditions like lymphatic, vascular, and pulmonary issues. The emphasis on at-home treatment and continuity of care aligns with broader healthcare trends towards decentralized care, cost efficiency, and patient empowerment. The company's performance metrics, particularly in revenue and Adjusted EBITDA growth, suggest effective navigation within this competitive landscape, leveraging its specialized product portfolio and integrated service model.

Comparison to Industry Standards

• The company utilizes a peer group of 17 publicly traded medical device and technology companies (including AngioDynamics, Glaukos Corporation, Inogen, Inc., SI-BONE, Inc., Axonics, Inc., and Nevro Corp.) for executive compensation benchmarking.
• The company's Total Stockholder Return (TSR) for 2025 was $64.53 (based on an initial $100 investment), which is lower than the S&P Healthcare Equipment Select Industry Index TSR of $77.53 for the same period, suggesting underperformance relative to its industry index.
• The company's revenue growth and Adjusted EBITDA growth for 2025 indicate strong operational performance within its sector, although specific comparisons to the growth rates of individual peer companies are not provided in this document.

Management Changes

Corporate Governance

Related Party Transactions

• No transactions exceeding $120,000 with related persons since January 1, 2025, are currently proposed or have occurred.
• The company has entered into indemnification agreements with its directors and executive officers.

Stakeholder Impact

• Shareholders: Potential positive impact from strong financial performance (revenue, Adjusted EBITDA growth), alignment of executive compensation with performance, and enhanced corporate governance through the proposed director removal amendment and existing policies (stock ownership, clawbacks).
• Patients: Continued benefit from the company's mission to provide advanced, clinically proven devices and continuity of care services for underserved chronic conditions, aiming to improve quality of life and reduce healthcare costs.
• Employees: Benefit from competitive compensation, comprehensive benefits, opportunities for growth, and a work environment free from harassment and discrimination, as outlined in the Human Capital Management strategy.
• Management: Executive officers' compensation is directly tied to company performance, incentivizing achievement of financial goals, while also being subject to robust governance and clawback policies.

Next Steps

• Elect nine directors at the Annual Meeting on May 6, 2026.
• Ratify the appointment of Grant Thornton LLP as independent registered public accounting firm for the year ending December 31, 2026.
• Approve, on an advisory basis, the 2025 compensation of named executive officers.
• Approve an amendment to the Company's Amended and Restated Certificate of Incorporation regarding director removal.
• Hold the next advisory vote on named executive officer compensation at the 2027 Annual Meeting of Stockholders.
• Stockholders to submit proposals for the 2027 Annual Meeting between January 6, 2027, and February 5, 2027.
• Stockholders to provide notice for soliciting proxies for director nominees for the 2027 Annual Meeting by March 8, 2027.

Key Dates

Recommendation

The company demonstrates solid financial performance with revenue and Adjusted EBITDA exceeding targets, indicating effective operational management. The commitment to strong corporate governance and performance-linked executive compensation are positive signals. However, the underperformance in Total Stockholder Return relative to the S&P Healthcare Equipment Select Industry Index suggests that while operations are strong, the stock's market perception or broader industry headwinds may be limiting its appreciation. A 'hold' recommendation is appropriate as the company shows fundamental strength but lacks clear catalysts for significant outperformance against its peers based solely on this proxy statement.

Keywords

Tactile Systems Technology, Tactile Medical, Proxy Statement, Executive Compensation, Corporate Governance, Director Election, Annual Meeting, Financial Performance, Revenue, Adjusted EBITDA, Medical Device, Healthcare Technology, Shareholder Vote, ESG